FCCC LOGO Faculty Publications
Johnson SB , Soulos PR , Shafman TD , Mantz CA , Dosoretz AP , Ross R , Finkelstein SE , Collins SP , Suy S , Brower JV , Ritter MA , King CR , Kupelian PA , Horwitz EM , Pollack A , Abramowitz MC , Hallman MA , Faria S , Gross CP , Yu JB
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer
Radiother Oncol. 2016 Nov;121(2) :294-298
Back to previous list
Abstract
BACKGROUND AND PURPOSE: Evaluate changes in bowel, urinary and sexual patient-reported quality of life following treatment with moderately hypofractionated radiotherapy (<5Gray/fraction) or stereotactic body radiation therapy (SBRT;5-10Gray/fraction) for prostate cancer. MATERIALS AND METHODS: In a pooled multi-institutional analysis of men treated with moderate hypofractionation or SBRT, we compared minimally detectable difference in bowel, urinary and sexual quality of life at 1 and 2years using chi-squared analysis and logistic regression. RESULTS: 378 men received moderate hypofractionation compared to 534 men who received SBRT. After 1year, patients receiving moderate hypofractionation were more likely to experience worsening in bowel symptoms (39.5%) compared to SBRT (32.5%; p=.06), with a larger difference at 2years (37.4% versus 25.3%, p=.002). Similarly, patients receiving moderate fractionation had worsening urinary symptom score compared to patients who underwent SBRT at 1 and 2years (34.7% versus 23.1%, p<.001; and 32.8% versus 14.0%, p<.001). There was no difference in sexual symptom score at 1 or 2years. After adjusting for age and cancer characteristics, patients receiving SBRT were less likely to experience worsening urinary symptom scores at 2years (odds ratio: 0.24[95%CI: 0.07-0.79]). CONCLUSIONS: Patients who received SBRT or moderate hypofractionation have similar patient-reported change in bowel and sexual symptoms, although there was worse change in urinary symptoms for patients receiving moderate hypofractionation.
Notes
Johnson, Skyler Bryce Soulos, Pamela R Shafman, Timothy D Mantz, Constantine A Dosoretz, Arie P Ross, Rudi Finkelstein, Steven E Collins, Sean P Suy, Simeng Brower, Jeffrey V Ritter, Mark A King, Christopher R Kupelian, Patrick A Horwitz, Eric M Pollack, Alan Abramowitz, Matthew C Hallman, Mark A Faria, Sergio Gross, Cary P Yu, James B eng Ireland 2016/11/29 06:00 Radiother Oncol. 2016 Nov;121(2):294-298. doi: 10.1016/j.radonc.2016.10.013. Epub 2016 Nov 24.